Sections |
| Title | Starting Page | Number of Pages |
|---|
| CHAPTER 1 GLOBAL MARKET ANALYSIS | 1 | 2 |
| 1.1 Anti-asthmatic market analysis by drug class | 2 | 1 |
| Overview of global anti-asthmatic market | 2 | 3 |
| Key trends in the global asthma market | 5 | 2 |
| 1.2 Beta2-agonists | 8 | 1 |
| Overview of the global beta2-agonist market | 8 | 2 |
| Key product sales in 2001 | 10 | 1 |
| Key trends in the global beta2-agonist market | 11 | 1 |
| Comparison of key brands in beta2-agonist class | 12 | 1 |
| Serevent (salmeterol) | 14 | 1 |
| Drug overview | 14 | 1 |
| Cross-indication and reformulation | 15 | 1 |
| SWOT analysis | 16 | 1 |
| Ventolin (albuterol) | 17 | 1 |
| Drug overview | 17 | 1 |
| Reformulation and cross-indication | 18 | 1 |
| SWOT analysis | 19 | 1 |
| Foradil (formoterol) | 20 | 1 |
| Drug overview | 20 | 2 |
| Approval in the US | 21 | 1 |
| SWOT analysis | 22 | 1 |
| Oxis (formoterol) | 23 | 1 |
| Drug overview | 23 | 1 |
| Drivers of future growth | 24 | 1 |
| SWOT analysis | 24 | 1 |
| 1.3 Corticosteroids | 25 | 1 |
| Overview of the global corticosteroid market | 26 | 2 |
| Key product sales in 2001 | 27 | 1 |
| Key trends in the global corticosteroid market | 28 | 2 |
| Comparison of key brands in the corticosteroid class | 30 | 1 |
| Flovent (fluticasone) | 31 | 1 |
| Drug overview | 31 | 1 |
| Line extensions: Cross-indication | 32 | 1 |
| Line extensions: Reformulation | 32 | 1 |
| Patent expiry | 33 | 1 |
| SWOT analysis | 33 | 1 |
| Pulmicort (budesonide) | 34 | 1 |
| Drug overview | 34 | 1 |
| Growth driver: Pulmicort Respules | 35 | 1 |
| Extending patent protection | 35 | 1 |
| SWOT analysis | 36 | 1 |
| 1.4 Combination products | 37 | 1 |
| Overview of the global combination product market | 37 | 2 |
| Key product sales in 2001 | 38 | 1 |
| Comparison of key brands in the combination product class | 39 | 1 |
| Advair (salmeterol & fluticasone) | 40 | 1 |
| Drug overview | 40 | 1 |
| Advair performance in 2001 | 41 | 1 |
| Future drivers of growth | 42 | 1 |
| SWOT analysis | 43 | 1 |
| Symbicort (formoterol & budesonide) | 44 | 1 |
| Drug overview | 44 | 1 |
| Key clinical trials | 45 | 2 |
| SWOT analysis | 47 | 1 |
| 1.5 Leukotriene antagonists | 48 | 1 |
| Overview of the global leukotriene antagonist market | 48 | 2 |
| Key trends in the global leukotriene antagonist market | 50 | 1 |
| Key product sales in 2001 | 51 | 1 |
| Comparison of key brands in leukotriene antagonist class | 52 | 1 |
| Singulair (montelukast) | 53 | 1 |
| Drug overview | 53 | 1 |
| Future drivers of growth | 54 | 1 |
| SWOT analysis | 55 | 1 |
| Accolate (zafirlukast) | 56 | 1 |
| Drug overview | 56 | 1 |
| SWOT analysis | 57 | 1 |
| 1.6 Anticholinergics | 58 | 1 |
| Overview of the global anticholinergic market | 58 | 2 |
| Key trends in the global anticholinergic market | 59 | 1 |
| Comparison of key brands in the anticholinergic class | 60 | 1 |
| 1.7 Respiratory NSAIDs | 61 | 1 |
| Overview of the global respiratory NSAIDs market | 61 | 2 |
| Key trends in the global respiratory NSAIDs market | 63 | 1 |
| Comparison of key brands in the respiratory NSAIDs class | 65 | 1 |
| 1.8 Xanthines | 66 | 1 |
| Overview of the global xanthine market | 66 | 2 |
| Key trends in the global xanthine market | 68 | 1 |
| Comparison of key brands in the xanthine class | 69 | 1 |
Tables |
| Title | Starting Page | Number of Pages |
|---|
| Global sales in the anti-asthmatic market by drug class, 1999- 2000 | 2 | 1 |
| Sales growth in the global anti-asthmatic market by drug class, 1996- 2000 | 5 | 1 |
| Beta2-agonist fact file | 8 | 1 |
| Global sales of the leading branded beta2-agonist drugs, 1999-2000 | 8 | 1 |
| Key beta2-agonist product sales, 2001 | 10 | 1 |
| Sales growth in the beta2-agonist market, 1996-2000 | 11 | 1 |
| Summary of leading beta2-agonist drug SWOT analyses | 13 | 1 |
| Serevent: key facts | 14 | 1 |
| Ventolin: key facts | 17 | 1 |
| Foradil: key facts | 20 | 1 |
| Oxis: key facts | 23 | 1 |
| Corticosteroids fact file | 25 | 1 |
| Global sales of the leading branded corticosteroid drugs, 1999-2000 | 26 | 1 |
| Key corticosteroid product sales, 2001 | 28 | 1 |
| Sales growth in the corticosteroid market, 1996-2000 | 28 | 1 |
| Summary of leading corticosteroid drug SWOT analyses | 30 | 1 |
| Flovent: key facts | 31 | 1 |
| Pulmicort: key facts | 34 | 1 |
| Combination products fact file | 37 | 1 |
| Global sales of the leading branded combination product drugs, 1999-2000 | 37 | 1 |
| Key combination product sales, 2001 2000-01 | 38 | 1 |
| Summary of leading combination product SWOT analyses | 39 | 1 |
| Advair: key facts | 40 | 1 |
| Symbicort: key facts | 44 | 1 |
| Leukotriene antagonist fact file | 48 | 1 |
| Global sales of the leading branded leukotriene antagonist drugs, 1999-2000 | 48 | 1 |
| Sales growth in the leukotriene antagonist market, 1996-2000 | 50 | 1 |
| Key leukotriene antagonist product sales, 2001 | 51 | 1 |
| Summary of leading leukotriene antagonist product SWOT analyses | 52 | 1 |
| Singulair: key facts | 53 | 1 |
| Accolate: key facts | 56 | 1 |
| Anticholinergics fact file | 58 | 1 |
| Global sales of the leading branded anticholinergic drugs, 1999-2000 | 58 | 1 |
| Sales growth in the anticholinergic market, 1996-2000 | 59 | 1 |
| Summary of leading anticholinergic product SWOT analyses | 60 | 1 |
| Respiratory NSAIDs fact file | 61 | 1 |
| Global sales of the leading branded respiratory NSAIDs, 1999-2000 | 61 | 1 |
| Sales growth in the respiratory NSAIDs market, 1996-2000 | 63 | 1 |
| Summary of leading respiratory NSAIDs SWOT analyses | 65 | 1 |
| Xanthine fact file | 66 | 1 |
| Global sales of the leading branded xanthine drugs, 1999- 2000 | 66 | 1 |
| Sales growth in the xanthine market, 1996-2000 | 68 | 1 |
| Summary of leading xanthine SWOT analyses | 69 | 1 |
Graphs |
| Title | Starting Page | Number of Pages |
|---|
| Figure 1: Growth And Sales Of Drug Classes, 1999-2000 | 4 | 1 |
| Figure 2: Trends In The Global Sales Of Anti-Asthmatics By Drug Class, 1996-2000 | 7 | 1 |
| Figure 3: Growth And Sales Of Leading beta2-Agonist Drugs, 1999-2000 | 10 | 1 |
| Figure 4: Trends In Global Sales Of beta2-Agonist Products, 1996-2000 | 12 | 1 |
| Figure 5: Key Factors In The Market Dynamics Of Serevent | 16 | 1 |
| Figure 6: Key Factors In The Market Dynamics Of Ventolin | 19 | 1 |
| Figure 7: Key Factors In The Market Dynamics Of Foradil | 22 | 1 |
| Figure 8: Key Factors In The Market Dynamics Of Oxis | 24 | 1 |
| Figure 9: Growth And Sales Of Leading Corticosteroid Drugs, 1999-2000 | 27 | 1 |
| Figure 10: Trends In Global Sales Of Corticosteroid Products, 1996-2000 | 29 | 1 |
| Figure 11: Key Factors In The Market Dynamics Of Flovent | 33 | 1 |
| Figure 12: Key Factors In The Market Dynamics Of Pulmicort | 36 | 1 |
| Figure 13: Key Factors In The Market Dynamics Of Advair | 43 | 1 |
| Figure 14: Key Factors In The Market Dynamics Of Symbicort | 47 | 1 |
| Figure 15: Growth And Sales Of Leading Leukotriene Antagonist Drugs, 1999-2000 | 49 | 1 |
| Figure 16: Trends In Global Sales Of Leukotriene Antagonist Products, 1996-2000 | 51 | 1 |
| Figure 17: Key Factors In The Market Dynamics Of Singulair | 55 | 1 |
| Figure 18: Key Factors In The Market Dynamics Of Accolate | 57 | 1 |
| Figure 19: Trends In Global Sales Of Anticholinergic Products, 1996-2000 | 60 | 1 |
| Figure 20: Growth And Sales Of Leading Respiratory NSAIDs, 1999-2000 | 62 | 1 |
| Figure 21: Trends In Global Sales Of Respiratory NSAIDs, 1996-2000 | 64 | 1 |
| Figure 22: Growth And Sales Of Leading Xanthine Drugs, 1999-2000 | 67 | 1 |
| Figure 23: Trends In Global Sales Of Xanthine Products, 1996-2000 | 69 | 1 |
